AVRO - Avrobio Inc Stock Price, Fair Value and News

$40.86+1.98 (+5.09%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AVRO Price Action

Last 7 days

5.5%

Last 30 days

12.6%

Last 90 days

137.7%

Trailing 12 Months

167.5%

AVRO RSI Chart

AVRO Valuation

Market Cap

602.8M

Price/Earnings (Trailing)

-7.97

Price/Sales (Trailing)

6.42

EV/EBITDA

-12.55

Price/Free Cashflow

-21.37

AVRO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AVRO Fundamentals

AVRO Revenue

Revenue (TTM)

105.9M

Rev. Growth (Yr)

8.55%

Rev. Growth (Qtr)

-10.22%

AVRO Earnings

Earnings (TTM)

-75.6M

Earnings Growth (Yr)

17.97%

Earnings Growth (Qtr)

-39.69%

AVRO Profitability

EBT Margin

-40.44%

Return on Equity

-50.31%

Return on Assets

-44.84%

Free Cashflow Yield

-4.68%

AVRO Investor Care

Shares Dilution (1Y)

297.17%

Diluted EPS (TTM)

-21.84

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	0	0	84.9M	105.9M
2021	21.8M	42.8M	63.8M	0
2020	0	0	0	719.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Avrobio Inc

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

WEBSITE	avrobio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	78

Avrobio Inc Frequently Asked Questions

What is the ticker symbol for Avrobio Inc? What does AVRO stand for in stocks?

AVRO is the stock ticker symbol of Avrobio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avrobio Inc (AVRO)?

As of Mon Nov 18 2024, market cap of Avrobio Inc is 602.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVRO stock?

You can check AVRO's fair value in chart for subscribers.

Is Avrobio Inc a good stock to buy?

The fair value guage provides a quick view whether AVRO is over valued or under valued. Whether Avrobio Inc is cheap or expensive depends on the assumptions which impact Avrobio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVRO.

What is Avrobio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Nov 18 2024, AVRO's PE ratio (Price to Earnings) is -7.97 and Price to Sales (PS) ratio is 6.42. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVRO PE ratio will change depending on the future growth rate expectations of investors.